Publications by authors named "Richard Bethell"

Claim this Profile
N
Novel L-nucleoside analogue, 5-fluorotroxacitabine, displays potent efficacy against acute myeloid leukemia.
Aniket Bankar, Thirushi Piyumika Siriwardena, Biljana Rizoska, Christina Rydergård, Helen Kylefjord, Richard Bethell

Haematologica· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease-Modifying Effects of a Novel Cathepsin K Inhibitor in Osteoarthritis: A Randomized Controlled Trial.
Philip G Conaghan, Michael A Bowes, Sarah R Kingsbury, Alan Brett, Gwenael Guillard, Richard Bethell

Ann Intern Med· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subtype-specific analysis of the K65R substitution in HIV-1 that confers hypersusceptibility to a novel nucleotide-competing reverse transcriptase inhibitor.
Hong-Tao Xu, Susan P Colby-Germinario, Peter K Quashie, Richard Bethell, Mark A Wainberg

Antimicrob Agents Chemother· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of BI 207524, an indole diamide NS5B thumb pocket 1 inhibitor with improved potency for the potential treatment of chronic hepatitis C virus infection.
Pierre L Beaulieu, Paul C Anderson, Richard Bethell, Michael Bös, Yves Bousquet

J Med Chem· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Derivatives of imidazotriazine and pyrrolotriazine C-nucleosides as potential new anti-HCV agents.
Alistair G Draffan, Barbara Frey, Benjamin H Fraser, Brett Pool, Carlie Gannon, Richard C Bethell

Bioorg Med Chem Lett· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD160 isoforms and regulation of CD4 and CD8 T-cell responses.
Mohamed El-Far, Charles Pellerin, Louise Pilote, Jean-Francois Fortin, Ivan A D Lessard, Richard C Bethell

J Transl Med· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of the W153L substitution in HIV reverse transcriptase on viral replication and drug resistance to multiple categories of reverse transcriptase inhibitors.
Hong-Tao Xu, Susan P Colby-Germinario, Maureen Oliveira, Daniel Rajotte, Richard Bethell

Antimicrob Agents Chemother· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical profile of BI 224436, a novel HIV-1 non-catalytic-site integrase inhibitor.
Craig Fenwick, Ma'an Amad, Murray D Bailey, Richard Bethell, Michael Bös

Antimicrob Agents Chemother· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Synthesis of C-Nucleosides as Potential New Anti-HCV Agents.
Alistair G Draffan, Barbara Frey, Brett Pool, Carlie Gannon, Edward M Tyndall, Richard C Bethell

ACS Med Chem Lett· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1.
Lee D Fader, Eric Malenfant, Mathieu Parisien, Rebekah Carson, François Bilodeau, Richard Bethell

ACS Med Chem Lett· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Viral resistance in hepatitis C virus genotype 1-infected patients receiving the NS3 protease inhibitor Faldaprevir (BI 201335) in a phase 1b multiple-rising-dose study.
Kristi L Berger, Lisette Lagacé, Ibtissem Triki, Mireille Cartier, Martin Marquis, Richard Bethell

Antimicrob Agents Chemother· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A simplified approach to predict CYP3A-mediated drug-drug interactions at early drug discovery: validation with clinical data.
Nathalie Rioux, Joëlle Batonga, Federico Colombo, Jonathan Massé, Christine Zouki, Richard C Bethell

Xenobiotica· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of potent and orally bioavailable nucleotide competing reverse transcriptase inhibitors: in vitro and in vivo optimization of a series of benzofurano[3,2-d]pyrimidin-2-one derived inhibitors.
Claudio F Sturino, Yves Bousquet, Clint A James, Patrick DeRoy, Martin Duplessis, Richard Bethell

Bioorg Med Chem Lett· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of benzofurano[3,2-d]pyrimidin-2-ones, a new series of HIV-1 nucleotide-competing reverse transcriptase inhibitors.
Martin Tremblay, Richard C Bethell, Michael G Cordingley, Patrick DeRoy, Jianmin Duan

Bioorg Med Chem Lett· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nucleotide competing reverse transcriptase inhibitors: discovery of a series of non-basic benzofurano[3,2-d]pyrimidin-2-one derived inhibitors.
Clint A James, Patrick DeRoy, Martin Duplessis, Paul J Edwards, Teddy Halmos, Richard Bethell

Bioorg Med Chem Lett· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of phosphatidylinositol-4-kinase IIIα as a hepatitis C virus drug target.
Frédéric H Vaillancourt, Martine Brault, Louise Pilote, Nathalie Uyttersprot, Elias T Gaillard, Richard C Bethell

J Virol· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The liver partition coefficient-corrected inhibitory quotient and the pharmacokinetic-pharmacodynamic relationship of directly acting anti-hepatitis C virus agents in humans.
Jianmin Duan, Gordon Bolger, Michel Garneau, Ma'an Amad, Joëlle Batonga, Richard C Bethell

Antimicrob Agents Chemother· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short communication: Phenotypic protease inhibitor resistance and cross-resistance in the clinic from 2006 to 2008 and mutational prevalences in HIV from patients with discordant tipranavir and darunavir susceptibility phenotypes.
Richard Bethell, Joseph Scherer, Myriam Witvrouw, Agnes Paquet, Eoin Coakley

AIDS Res Hum Retroviruses· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cross-species absorption, metabolism, distribution and pharmacokinetics of BI 201335, a potent HCV genotype 1 NS3/4A protease inhibitor.
Jianmin Duan, Chan-Loi Yong, Michel Garneau, Ma'an Amad, Gordon Bolger, Richard C Bethell

Xenobiotica· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of inhibitors of HIV-1 capsid assembly.
Lee D Fader, Richard Bethell, Pierre Bonneau, Michael Bös, Yves Bousquet

Bioorg Med Chem Lett· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.
Peter W White, Montse Llinàs-Brunet, Ma'an Amad, Richard C Bethell, Gordon Bolger

Antimicrob Agents Chemother· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replication.
Frédéric H Vaillancourt, Louise Pilote, Mireille Cartier, Julie Lippens, Michel Liuzzi, Richard C Bethell

Virology· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of apricitabine and other nucleoside reverse transcriptase inhibitors on replication of mitochondrial DNA in HepG2 cells.
Michel P de Baar, Esther R de Rooij, Karlijn G M Smolders, Harm B van Schijndel, Eveline C Timmermans, Richard Bethell

Antiviral Res· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apricitabine: a novel deoxycytidine analogue nucleoside reverse transcriptase inhibitor for the treatment of nucleoside-resistant HIV infection.
Mark A Wainberg, Pedro Cahn, Richard C Bethell, James Sawyer, Susan Cox

Antivir Chem Chemother· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients.
Pedro Cahn, Isabel Cassetti, Robin Wood, Praphan Phanuphak, LeeAnn Shiveley, Richard C Bethell

AIDS· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis